Physician profile
Charles Hall
NPI 1013917459
$1,584.92
in general payments reported to CMS, 2019-2025
25 companies · $94.63 in 2025
The $94.63 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $381 · 2021: $113 · 2022: $52.36 · 2023: $31.76 · 2024: $133 · 2025: $94.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $259.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $533.18 | 2019-2021 | |
| Abbott Laboratories | $227.27 | 2024-2025 | Eterna, Proclaim, Axium |
| Collegium Pharmaceutical, INC. | $190.12 | 2019-2020 | |
| Horizon Therapeutics Plc | $107.80 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $98.79 | 2019-2021 | |
| Pfizer INC. | $74.02 | 2019 | |
| Scilex Pharmaceuticals INC. | $67.22 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.40 | 2019 | |
| Arbor Pharmaceuticals, INC. | $42.94 | 2019 | |
| Boston Scientific Corporation | $31.76 | 2023 | Wavewriter Alpha Prime 16 |
| Orexo US, INC. | $27.22 | 2019-2020 | |
| Daiichi Sankyo INC. | $23.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.38 | 2019 | |
| Shionogi INC | $18.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.46 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $17.05 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.64 | 2019 | |
| Medtronic USA, INC. | $13.49 | 2020 | |
| Redhill Biopharma INC. | $11.64 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.